NCT07263178 A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
| NCT ID | NCT07263178 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Condition | Metastatic Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-11-07 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-11-07 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.
Eligibility Criteria
Inclusion Criteria: * Patients who have signed the informed consent after receiving information about the purpose and method of this study. * Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions. * Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy). * Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date. Exclusion Criteria: * Female patients who are pregnant, have childbearing potential, or are breastfeeding. * Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study. * Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07263178 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Metastatic Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07263178 currently recruiting?
Yes, NCT07263178 is actively recruiting participants. Contact the research team at syoh@boryung.co.kr for enrollment information.
Where is the NCT07263178 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07263178 clinical trial?
NCT07263178 is sponsored by Boryung Pharmaceutical Co., Ltd. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.